teamLab Planets TOKYO Wins the World Travel Awards for “Asia’s Leading Tourist Attraction 2023”
11.9.2023 21:00:00 EEST | Business Wire | Press release
teamLab Planets TOKYO in Toyosu, Tokyo was announced as the winner of the World Travel Awards 2023 for “Asia’s Leading Tourist Attraction 2023” on September 6 at the ceremony in Ho Chi Minh.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230910702671/en/
teamLab Planets, a body immersive museum in Toyosu, Tokyo, wins the World Travel Awards for “Asia’s Leading Tourist Attraction 2023”. (teamLab Planets, Toyosu, Tokyo / Photo: teamLab)
Following this ceremony, the winner from each region across the world will be nominated to win the “World's Leading Tourist Attraction 2023” in December, 2023. The World Travel Awards, which has its 30th anniversary this year, celebrates the best travel destinations based on votes not only from travel industry professionals but also regular voters. Wall Street Journal has described it as the travel “industry's equivalent of the Oscar's".
The nominees for Asia’s Leading Tourist Attraction 2023 were as follows (in alphabetical order):
Angkor Temples (Cambodia)
Borobudur (Indonesia)
Great Wall of China
Ha Long Bay (Vietnam)
Intramuros (Philippines)
Sengan-en and Shoko Shuseikan Museum (Kagoshima, Japan)
Taj Mahal (India)
teamLab SuperNature Macao (China)
Terracotta Warriors (China)
The Forbidden City (China)
Tokyo Imperial Palace (Japan)
Victoria Peak (Hong Kong)
https://www.worldtravelawards.com/award-asias-leading-tourist-attraction-2023
About the World Travel Awards
World Travel Awards was established in 1993 to acknowledge, reward and celebrate excellence across all key sectors of the travel, tourism and hospitality industries. Today, the World Travel Awards™ brand is recognised globally as the ultimate hallmark of industry excellence.
Votes are cast by travel and hospitality professionals as well as consumers from over 200 countries across the globe.
Website: http://www.worldtravelawards.com/
About teamLab Planets TOKYO
teamLab Planets, which celebrated its 5th anniversary last July, has renewed several artwork spaces and unveiled a new installation, creating an even more immersive experience. In addition, due to its popularity, the museum, originally scheduled to close at the end of 2023, has been extended to the end of 2027.
teamLab Planets is a museum where you walk through water, and a garden where you become one with the flowers. It comprises 4 large-scale artwork spaces and 2 gardens created by art collective teamLab.
teamLab Planets TOKYO
https://planets.teamlab.art/tokyo/
#teamLabPlanets
July 7, 2018 - End of 2027
Toyosu 6-1-16, Koto-ku, Tokyo
Press Kit
https://www.dropbox.com/sh/ir7d2aui794eo6z/AAChbzX5wPsQm8cgkQ2ViFD4a?dl=0
Media Inquiries
https://www.teamlab.art/contact/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230910702671/en/
Contact information
PLANETS Co., Ltd. Public Relations Department
E-mail: pr-info@planets.art
Interview: https://forms.gle/fAtnDKLpQKFME6XR9
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f
Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 15:00:00 EET | Press release
Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end workflows spanning onboarding, KYC, AML, fraud, underwriting, payments, disputes, servicing, and collections. For
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom